The influenza virus is highly contagious diseases of people, birds and mammals. Approximately 250 000- 500 000 deaths are caused by influenza epidemics worldwide yearly, and the death number may be up to millions in a possible influenza pandemic. Vaccination is the most cost-effective way to reduce the considerable disease burden of seasonal influenza. Although seasonal influenza vaccines are effective, their performance in the elderly and immunocompromised individuals would benefit from improvement. Major problems related to the development and production of pandemic influenza vaccines are response time and production capacity as well as vaccine efficacy and safety. Reverse genetics techniques can speed up the generation of seed viruses and new mathematical modelling methods improve vaccine strain selection. Using vaccines based on recombinant proteins, we avoid the risks associated with the introduction of the virus into the body, even inactivated. In this paper, we have got a highly purified recombinant fusion protein composed of fragments of the hemagglutinin of influenza viruses A and B. As adjuvant we used components of flagellin. We used the most immunogenic and conserved areas of hemagglutinin H1, H3, H5 and B, which cause the formation of specific antibodies which can cross-react with homologous epitopes among the various strains of influenza A and B. Vaccine efficacy is increased by using multiple epitopes of various proteins. The aim of this study was to clone and express the hybrid recombinant protein Flu-Chim, containing immunogenic epitopes of influenza A/H1N1, A/H3N2, A/H5N1 and B fused with fragments of flagellin in Escherichia coli expression system and its subsequent purification. During the study was created high-yield E. coli strain, which produces the recombinant protein Flu-Chim, selected the optimal protocol of induction of the gene encoding the protein. The protein was purified using metal affinity chromatography. The purity of the final preparation reached 98%. In the future, we are going to study the immunogenic properties of the protein and use it as a component of the candidate vaccine against influenza.